Resources Year All 2019 2018 2017 2016 2015 2014 2013 2012 2010 Go Search Presentation Preclinical and Early Clinical Activity of the Oral Selective Inhibitor of Nuclear Export (SINE) Exportin 1 (XPO1) Antagonist Selinexor (KPT-330) in Patients (pts) with Platinum Resistant/Refractory Ovarian Cancer (OvCa) PDF (3.50 MB) Read MorePresentation Clinical Activity of the Oral Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) in Patients with Head & Neck Squamous Cell Carcinoma (HN-SCC) PDF (3.11 MB) Read MorePresentation Selinexor (KPT-330), an Oral, Selective Inhibitor of Nuclear Export (SINE) Shows Anti-Prostate Cancer (PrCa) Activity Preclinically & Disease Control in Patients (pts) with Chemotherapy Refractory, Castrate-Resistant Prostate Cancer (CRPC) PDF (2.86 MB) Read MorePaper Novel Small Molecule XPO1/CRM1 Inhibitors Induce Nuclear Accumulation of TP53, Phosphorylated MAPK and Apoptosis in Human Melanoma Cells External Link Read MorePaper Selective inhibitors of nuclear export (SINE) as novel therapeutics for prostate cancer External Link Read MorePaper Biologic activity of the novel orally bioavailable selective inhibitor of nuclear export (SINE) KPT-335 against canine melanoma cell lines External Link Read MorePaper Verdinexor, a novel Selective Inhibitor of Nuclear Export (SINE), reduces Influenza A virus replication in vitro and in vivo. External Link Read MorePaper KPT-330 has antitumour activity against non-small cell lung cancer External Link Read MorePaper A structure-based virtual screening approach for discovery of covalently bound ligands External Link Read MorePresentation Evaluation of the novel, orally bioavailable selective inhibitor of nuclear export (SINE) KPT-335 (verdinexor) in spontaneous canine cancer: Results of phase I and phase II clinical trials PDF (592.72 KB) Read More Previous 1 … 15 16 17 18 19 … 22 Next